Clinical efficacy of mouse nerve growth factor in the treatment of sudden deafness.
- Author:
Ting XU
;
Dajiang XIAO
;
Sihai WU
;
Yuan YUAN
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Female;
Hearing Loss, Sudden;
drug therapy;
Humans;
Male;
Middle Aged;
Nerve Growth Factor;
therapeutic use;
Retrospective Studies;
Treatment Outcome;
Young Adult
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2014;28(10):735-737
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the clinical efficacy of mouse nerve growth factor (NGF) in the treatment of sudden deafness.
METHOD:A retrospective analysis was performed on 115 cases of hospitalized patients who were suffered from sudden deafness. Patients were divided into two groups according to treatment medicine. Control group: patients were treated with intravenous vasodilators, energy mixture, steroid pulse therapy, and methylcobalamin neurotrophic therapy. NGF group: intramuscular NGF treatment was added on the basis of conventional therapy mentioned above. Both treatments lasted 14 days, the total efficiency were compared. Patients were further divided into sub-groups according to age, duration and the level of pre-treatment PTA, and the treatment efficiency was further compared. By SPSS 11.0 statistical analysis, a P < 0.05 was considered as statistical significant difference.
RESULT:(1) The total efficiency of NGF group was significantly higher than control group. (2) Regard of age, the efficiency of NGF treatment group was significantly higher than control group. (3) For the patients whose duration were less than 7 d, or the PTA < or = 60 dBHL, the efficiency of NGF group were significantly higher. For the patients whose duration were more than 7 d, or the PTA>60 dBHL, the efficiency of NGF therapy was not superior to the traditional treatment.
CONCLUSION:NGF can significantly improve the symptom of patients with short duration or low PTA. For this kind of patients, NGF adjuvant therapy should be recommended. For the patients with longer duration and higher level of PTA, NGF therapy is not advocated. NGF treatment should not be in consideration of the age.
